Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
MannKind Community
NasdaqGM:MNKD Community
1
Narratives
written by author
1
Comments
on narratives written by author
11
Fair Values set
on narratives written by author
Create a narrative
MannKind
Popular
Undervalued
Overvalued
Community Investing Ideas
MannKind
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Pipeline Progress And International Expansion Will Strengthen Future Earnings Potential
Key Takeaways International market expansion and pediatric indications significantly boost Afrezza's revenue potential and broaden patient reach. Collaborations and a diversified development pipeline enhance future revenue, with a solid balance sheet supporting strategic investments.
View narrative
US$10.29
FV
55.5% undervalued
intrinsic discount
11.98%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
6 days ago
author updated this narrative
Your Valuation for
MNKD
MNKD
MannKind
Your Fair Value
US$
Current Price
US$4.58
5.3% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-368m
522m
2015
2018
2021
2024
2025
2027
2030
Revenue US$522.0m
Earnings US$50.4m
Advanced
Set Fair Value